Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer
Year: 2025
Type: article
Language: en
Topic: CAR-T cell therapy research
Authors and affiliations:
raw_author_name: Sangwoo Park
raw_affiliation_strings: Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA, USA
Harvard Medical School, Boston, MA, USA
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA
raw_author_name: Cassidy E. Ho
raw_affiliation_strings: Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA, USA
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA
raw_author_name: Eli P. Darnell
raw_affiliation_strings: Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA, USA
Harvard Medical School, Boston, MA, USA
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA
raw_author_name: Alexandra N. Wolff
raw_affiliation_strings: Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA, USA
Harvard Medical School, Boston, MA, USA
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA
raw_author_name: Hana Takei
raw_affiliation_strings: Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA, USA
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA
raw_author_name: Filippo Birocchi
raw_affiliation_strings: Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA, USA
Harvard Medical School, Boston, MA, USA
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA
raw_author_name: Amanda A. Bouffard
raw_affiliation_strings: Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA, USA
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA
raw_author_name: Diego Salas-Benito
raw_affiliation_strings: Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA, USA
Harvard Medical School, Boston, MA, USA
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA
raw_author_name: Giulia Escobar
raw_affiliation_strings: Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA, USA
Harvard Medical School, Boston, MA, USA
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA
raw_author_name: Mark B. Leick
raw_affiliation_strings: Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA, USA
Harvard Medical School, Boston, MA, USA
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA
raw_author_name: Adele Mucci
raw_affiliation_strings: Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA, USA
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA
raw_author_name: Trisha R. Berger
raw_affiliation_strings: Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA, USA
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA
raw_author_name: Marcela V. Maus
raw_affiliation_strings: Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA, USA. mvmaus@mgh.harvard.edu
Harvard Medical School, Boston, MA, USA. mvmaus@mgh.harvard.edu
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA. mvmaus@mgh.harvard.edu
Harvard Medical School, Boston, MA, USA
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA